Skip to main content
SpringerLink
Log in

Levodopa and orphenadrine hydrochloride in parkinsonism

  • Originals
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Summary

In Parkinsonian patients on maximum tolerated doses of levodopa, a double-blind, cross-over trial showed that greater benefit was conferred by additional orphenadrine hydrochloride than by placebo. Further observations suggest that the benefit conferred by supplemental orphenadrine is lost if the drug is withdrawn either suddenly or gradually. The greatest improvements were seen in balance, posture, handwriting, performance of domestic tasks, dressing and feeding.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Hornykiewicz, O.: Histochemistry, biochemistry and pharmacology of brain catecholamines in extrapyramidal syndromes in man. Paper read at Symposium ‘Monoamines and Central Grey Nuclei’ at Clinique Bel-Air, Geneva, September 14 (1970).

  2. Weintraub, M.I., Van Woert, M.H.: Reversal by levodopa of cholinergic hypersensitivity in Parkinson's disease. New Engl. J. med.284, 412–415 (1971).

    Google Scholar 

  3. Calne, D.B., Spiers, A.S.D., Stern, G.M., Laurence, D.R., Armitage, P.: L-dopa in idiopathic Parkinsonism. Lancet1969 II, 973–976.

    Google Scholar 

  4. Hunter, K.R., Stern, G.M., Laurence, D.R., Armitage, P.: Amantadine in Parkinsonism. Lancet1970 I, 1127–1129.

    Google Scholar 

  5. —— —— —— —— Combined treatment of Parkinsonism with L-dopa and amantadine. Lancet1970 II, 566.

    Google Scholar 

  6. Calne, D.B.: Parkinsonism: physiology, pharmacology and treatment. London: Edward Arnold (Publishers) Ltd., 1970.

    Google Scholar 

  7. Yahr, M. D.: Discussion, drug-induced relief of experimental tremor. Neurology (Minneap.)20, 89–95 (1970).

    Google Scholar 

  8. Mones, R.J., Elizan, T.S., Siegel, G.J.: Evaluation of L-dopa therapy in Parkinson's disease. New York J. med.70, 2309–2318 (1970).

    Google Scholar 

  9. Rivera-Calimlim, L., Dujovne, C.A., Morgan, J.P., Lasagna, L., Bianchine, J.R.: L-dopa treatment failure: explanation and correction. Brit. med J.1970 IV, 93–94.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinical Pharmacology Section, Medical Unit, and Neurological Unit, University College Hospital Medical School, London, Great Britain

    R. K. Whyte, K. R. Hunter, D. R. Laurence, G. M. Stern & P. Armitage

  2. Department of Medical Statistics and Epidemiology, London School of Hygiene and Tropical Medicine, London, Great Britain

    R. K. Whyte, K. R. Hunter, D. R. Laurence, G. M. Stern & P. Armitage

Authors
  1. R. K. Whyte
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K. R. Hunter
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D. R. Laurence
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G. M. Stern
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. P. Armitage
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Whyte, R.K., Hunter, K.R., Laurence, D.R. et al. Levodopa and orphenadrine hydrochloride in parkinsonism. Eur J Clin Pharmacol 4, 18–21 (1971). https://doi.org/10.1007/BF00568893

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00568893

Key words

Search

Navigation